PharmaSecure secures US$3.9m in funding

Published: 28-Oct-2011
Finance

To develop drug authentication technologies and software


PharmaSecure, a developer of drug authentication technologies and software, has closed a US$3.9m funding round, backed by Innovation Endeavors, Gray Ghost Ventures, Healthtech Capital and the TEEC Angel Fund.

PharmaSecure plans to use the money to support new applications following the Indian government’s mandate that all drugs exported from the country must include unique serial numbers and barcodes by July 2012.

India is expected to export pharmaceuticals worth US$8bn next year.

  • Companies:
  • PharmaSecure
See more

You may also like

Finance

Berry Global invests to increase production capacity for healthcare products

Read more
Berry Global Group has invested in additional assets and manufacturing capabilities to increase its healthcare production capacity by up to 30% across three of its European sites

Trending Articles

  1. Seppic acquires BiotechMarine Owner Air Liquide reinforces position in healthcare ingredients
  2. Adult vaccination programmes deliver significant socio-economic benefits, study finds The study shows that adult immunisation programmes return 19x their initial investment, which could ease the pressure on health systems
  3. AstraZeneca to stop production of Pulmicort pMDI Agreements with SkyePharma expected to be terminated
  4. Berry Global invests to increase production capacity for healthcare products Berry Global Group has invested in additional assets and manufacturing capabilities to increase its healthcare production capacity by up to 30% across three of its European sites
  5. Teva to establish business venture in Korea with Handok First commercial deal for Teva in East Asian territory outside Japan

Upcoming event

ASGCT Annual Meeting 2024

7-11 May, 2024 | Meeting | Portland, OR See all

You may also like

Finance

Berry Global invests to increase production capacity for healthcare products

Berry Global Group has invested in additional assets and manufacturing capabilities to increase its healthcare production capacity by up to 30% across three of its European sites
Research & Development

Ipsen and Skyhawk Therapeutics partner to develop RNA-targeting drug candidates

The USD $1.8bn deal will support the development of novel RNA-modulating drugs using Skyhawk's proprietary technology
Manufacturing

Bristol Myers Squibb and Cellares partner to expand CAR-T manufacturing capabilities

Cellares will optimise and automate select Bristol Myers Squibb CAR-T cell therapies onto its high-throughput manufacturing program, the Cell Shuttle
Research & Development

SNIPR Biome receives funding to progress CRISPR medicine SNIPR001 into clinical trials

Phase 1b/2a trial will evaluate SNIPR001 for the prevention of E.coli infections in patients undergoing hematopoietic stem cell transplantation
Research & Development

SeaBeLife awarded over €1.5 million in i-Nov innovation competition

Funding for company’s SeaBeEYE project will be used to develop a new therapeutic approach for geographic atrophy, a form of age-related macular degeneration
Drug Delivery

Adult vaccination programmes deliver significant socio-economic benefits, study finds

The study shows that adult immunisation programmes return 19x their initial investment, which could ease the pressure on health systems
Regulatory

Policy vacuum risks UK becoming a medicines supply backwater

The UK becoming a "backwater" supply marker could jeopardise £18bn of NHS savings from newly off-patented drugs during the next five years
Subscribe now